Potential clinical benefits of warfarin in end‐stage cancers: A retrospective analysis
Abstract Background and Aims Coagulopathy and thromboembolism are common comorbidities in cancer, and anticoagulants, such as warfarin, are needed in specific situations. This study aimed to determine the clinical relevance of prothrombin time (PT) monitoring and the clinical usefulness of warfarin...
Main Authors: | Osamu Imataki, Takeshi Arai, Makiko Uemura |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Health Science Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/hsr2.956 |
Similar Items
-
STANDARDIZATION OF PROTHROMBIN TIME TEST AND EVALUATION OF QUALITY OF PATIENT MANAGEMENT WITH WARFARIN
by: A.H ZARGARZADEH, et al.
Published: (2000-12-01) -
Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery
by: Tomoki Takase, et al.
Published: (2018-05-01) -
Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article
by: Pall T. Onundarson, et al.
Published: (2021-10-01) -
The effect of COVID-19 pandemic on time in therapeutic range in patients using warfarin
by: Adem Aktan, et al.
Published: (2022-01-01) -
A Case Report of a Patient on Therapeutic Warfarin Who Died of COVID-19 Infection with a Sudden Rise in D-Dimer
by: Reita N. Agarwal, et al.
Published: (2021-10-01)